January 30, 2025 07:00 AM Eastern Standard Time EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. “We were pleased with the efforts of our […]
Other News
Viz.ai and Illuminate Expand Partnership to Improve Cerebral Aneurysm Patient Care
SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an expanded partnership with Softek Illuminate, Inc., an industry leader in the development of proprietary natural language processing (NLP) and AI software that discovers at-risk patients from electronic medical records (EMR), assesses disease severity, and […]
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study January 30, 2025 06:45 AM Eastern Standard Time RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced […]
AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the start of a Randomized Study of the Auryon Atherectomy System Used in Combination with […]
Rapid Medical™ Announces Enrollment in the First-Ever Study on the Cognitive Benefits of Thrombectomy for Ischemic Stroke Patients-Enabled by Advancements in Endovascular Devices
January 29, 2025 11:05 AM Eastern Standard Time SOUTHLAKE, Texas–(BUSINESS WIRE)–Rapid Medical™, a leading developer of active endovascular devices, announces the first patient enrolled in its COGNITIVE Study–the first to examine a link between mechanical thrombectomy and cognitive improvement. TIGERTRIEVER, the only active stent retriever, may uniquely preserve cognitive function with […]
Stereotaxis Announces First GenesisX Robotic System Order
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has received the first order for its latest generation robotic system, GenesisX™.
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. The interim data showed that a single intravenous dose of TX45 resulted in meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). In the trial, TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events.
Cagent Vascular Initiates the Serranator® POINT FORCE Observational Registry
WAYNE, Penn.–(BUSINESS WIRE)–Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the start of the POINT FORCE Registry, a post-market clinical follow-up study of the Serranator® PTA Serration Balloon Catheter. “What we endeavor to understand In POINT FORCE is the role Serranation can […]
Sirona Medical Taps Radiology IT Veteran Ken Kaufman to be CEO in Next Stage of Growth
SAN FRANCISCO, Jan. 28, 2025 /PRNewswire/ — Sirona Medical, a leader in cloud-native radiology workflow solutions, announced the appointment of Ken Kaufman as Chief Executive Officer. Kaufman is a seasoned executive and business builder with a distinguished career spanning radiology and…
Positron Corporation Announces Sale of Attrius PET and NeuSight PET-CT Scanners
Niagara Falls, NY, Jan. 28, 2025 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company specializing in PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices.



